Nexalin Technology (NXL), announced the completion and launch of phases one through ... remote monitoring, and clinical oversight of its HALO headset in both research and patient treatment settings.

This milestone builds upon phase one of the virtual clinic ... we can now facilitate clinical research on the HALO™ device while preparing for broader patient adoption. By creating a seamless ...

CERo Therapeutics Holdings, Inc. has announced that the Sarah Cannon Research Institute at the Colorado Blood Cancer Institute will be a key clinical trial site for its Phase 1 trial of CER-1236 ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose ...